CN107854454A - 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物 - Google Patents

用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物 Download PDF

Info

Publication number
CN107854454A
CN107854454A CN201710887079.8A CN201710887079A CN107854454A CN 107854454 A CN107854454 A CN 107854454A CN 201710887079 A CN201710887079 A CN 201710887079A CN 107854454 A CN107854454 A CN 107854454A
Authority
CN
China
Prior art keywords
pharmaceutical composition
diketopiperazine
sumatriptan
salt
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710887079.8A
Other languages
English (en)
Chinese (zh)
Inventor
安德里亚·勒龙-贝
格雷森·W·斯托厄尔
约瑟夫·J·古尔纳利
卓恩·M·卡尔森
马歇尔·格兰特
查得·C·斯穆尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of CN107854454A publication Critical patent/CN107854454A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201710887079.8A 2010-11-09 2011-11-09 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物 Pending CN107854454A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41177510P 2010-11-09 2010-11-09
US61/411,775 2010-11-09
US41233910P 2010-11-10 2010-11-10
US61/412,339 2010-11-10
CN2011800540606A CN103200940A (zh) 2010-11-09 2011-11-09 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800540606A Division CN103200940A (zh) 2010-11-09 2011-11-09 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物

Publications (1)

Publication Number Publication Date
CN107854454A true CN107854454A (zh) 2018-03-30

Family

ID=45048258

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710887079.8A Pending CN107854454A (zh) 2010-11-09 2011-11-09 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物
CN2011800540606A Pending CN103200940A (zh) 2010-11-09 2011-11-09 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011800540606A Pending CN103200940A (zh) 2010-11-09 2011-11-09 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物

Country Status (10)

Country Link
EP (2) EP3536368B1 (cg-RX-API-DMAC7.html)
JP (2) JP6092113B2 (cg-RX-API-DMAC7.html)
KR (1) KR101931392B1 (cg-RX-API-DMAC7.html)
CN (2) CN107854454A (cg-RX-API-DMAC7.html)
AU (1) AU2011326529B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013011549B1 (cg-RX-API-DMAC7.html)
CA (1) CA2817337C (cg-RX-API-DMAC7.html)
ES (1) ES2732818T3 (cg-RX-API-DMAC7.html)
MX (2) MX376862B (cg-RX-API-DMAC7.html)
WO (1) WO2012064892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
CN103599155B (zh) * 2013-11-27 2015-12-02 广州安健实业发展有限公司 治疗偏头痛的方法
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3288591A1 (en) * 2015-05-01 2018-03-07 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP3316865A4 (en) 2015-07-02 2019-01-23 Civitas Therapeutics, Inc. TRIPTAN POWDER FOR PULMONARY ADMINISTRATION
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1334723A (zh) * 1998-12-09 2002-02-06 维克特拉有限公司 粉末的改进或与粉末有关的改进
WO2009055742A2 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Delivery of active agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) * 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Glp-1에 의한 유해 효과의 예방 방법
US20110077272A1 (en) * 2008-02-01 2011-03-31 Vectura Limited Pulmonary formulations of triptans
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1334723A (zh) * 1998-12-09 2002-02-06 维克特拉有限公司 粉末的改进或与粉末有关的改进
WO2009055742A2 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Delivery of active agents

Also Published As

Publication number Publication date
AU2011326529B2 (en) 2015-07-30
EP3536368B1 (en) 2025-09-17
EP2637657A1 (en) 2013-09-18
BR112013011549A2 (pt) 2017-07-25
JP6092113B2 (ja) 2017-03-08
JP2013545748A (ja) 2013-12-26
AU2011326529A1 (en) 2013-05-02
MX376862B (es) 2025-03-07
CA2817337C (en) 2020-04-14
KR20140008314A (ko) 2014-01-21
CA2817337A1 (en) 2012-05-18
EP3536368A1 (en) 2019-09-11
BR112013011549B1 (pt) 2022-01-04
JP2017110026A (ja) 2017-06-22
CN103200940A (zh) 2013-07-10
EP2637657B1 (en) 2019-05-22
JP6458064B2 (ja) 2019-01-23
WO2012064892A1 (en) 2012-05-18
KR101931392B1 (ko) 2018-12-20
ES2732818T3 (es) 2019-11-26
MX2013005294A (es) 2013-12-06
MX340112B (es) 2016-06-27

Similar Documents

Publication Publication Date Title
JP6458064B2 (ja) ジケトピペラジンを含む治療のための組成物
CN101969928B (zh) 活性剂的递送
US20200405731A1 (en) Method and composition for administering prostaglandins
Mandal Inhaled insulin for diabetes mellitus
TW201113259A (en) Diketopiperazine microparticles with defined isomer contents
Tandon et al. Insulin therapy for diabetes epidemic: a patent review
Rashid et al. Newer devices and improved formulations of inhaled insulin
Mitta et al. An overview on pulmonary insulin
US20240390274A1 (en) Method and composition for treating obesity
Mahendralal et al. A Comprehensive Review of Design and Evaluation of a Breath-Actuated Inhaler for Technosphere Insulin: Enhancing Glycemic Control
Kumbhar et al. Novel route of inhaled insulin for diabetes treatment
Patton Pulmonary delivery of insulin
AU2017248512B2 (en) Method and composition for treating migraines
US20250288515A1 (en) Method and composition for treating lung diseases
Myrdal et al. Pulmonary Delivery of Drugs by Inhalation
HK40014359B (en) Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
HK40014359A (en) Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
Kelly Advances in Delivering Macromolecules
Al-Saweer Inhaled Insulin: A Truth or a Fallacy?

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180330

RJ01 Rejection of invention patent application after publication